Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial
Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, Im SA, Neven P, Lonshteyn A, Chandiwana D, Lanoue B, Fasching P (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S66-S66
Conference Proceedings Title: ANNALS OF ONCOLOGY
Event location: ONLINE
DOI: 10.1016/j.annonc.2020.03.243
Authors with CRIS profile
Involved external institutions
Curtin University
Australia (AU)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
Policy Analysis Inc (PAI)
United States (USA) (US)
Universidad Complutense de Madrid (UCM)
Spain (ES)
Novartis AG
Switzerland (CH)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Italy (IT)
Highlands Oncology Group
United States (USA) (US)
Centre Hospitalier Universitaire de Liège (CHU Liège)
Belgium (BE)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
Australia (AU)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
Policy Analysis Inc (PAI)
United States (USA) (US)
Universidad Complutense de Madrid (UCM)
Spain (ES)
Novartis AG
Switzerland (CH)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Italy (IT)
Highlands Oncology Group
United States (USA) (US)
Centre Hospitalier Universitaire de Liège (CHU Liège)
Belgium (BE)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
How to cite
APA:
Jerusalem, G., Delea, T., Martin Jimenez, M., De Laurentiis, M., Nusch, A., Beck, J.T.,... Fasching, P. (2020). Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial. In ANNALS OF ONCOLOGY (pp. S66-S66). ONLINE: AMSTERDAM: ELSEVIER.
MLA:
Jerusalem, G., et al. "Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial." Proceedings of the ESMO Breast Cancer Virtual Meeting, ONLINE AMSTERDAM: ELSEVIER, 2020. S66-S66.
BibTeX: Download